For biotechnology companies looking towards Europe, the opportunity is considerable—but so is the complexity. Accessing one of the world’s largest healthcare markets requires more than promising science. Companies must navigate sophisticated regulatory frameworks, secure capital, build the right partnerships and understand where best to establish their European operations.

These challenges—and the opportunities emerging alongside them—were at the centre of the session “Where Regulation Meets Opportunity: EMA and the Dutch Investment Climate,” held on 16 July at BIO Asia–Taiwan 2026 in Taipei.

Co-organised by the Netherlands Foreign Investment Agency (NFIA), the session brought together investment and regulatory experts to explore a proposition of growing relevance for Asia’s biotechnology sector: how the Netherlands can serve as a strategic entry point into the European life sciences market, while earlier engagement with regulators can help innovative medicines and technologies move more effectively towards development and commercialisation.

The Netherlands Makes Its Case as a Life Sciences Gateway

Opening the session, Lauren Liebe, Business Analyst, Life Science and Health at the Netherlands Foreign Investment Agency, introduced the breadth of the Dutch life sciences and health ecosystem.

For international companies, the Netherlands offers a combination that extends beyond geography. Its appeal lies in the proximity of scientific institutions, healthcare expertise, established pharmaceutical and biotechnology operations, specialised talent and access to the wider European market.

The presence of the European Medicines Agency in Amsterdam has added another dimension to this ecosystem, strengthening the Netherlands’ position at the intersection of science, regulation and commercial opportunity.

For Asian biotech companies considering international expansion, this creates an important strategic question: rather than viewing Europe simply as an export destination, should companies begin building their European regulatory, clinical and commercial strategies much earlier in their development journey?

The discussion in Taipei suggested that the answer increasingly points towards earlier engagement.

Capital Matters, but So Does the Investment Environment

The session also examined one of the most decisive factors influencing international expansion: access to capital and the broader financial environment in which companies operate.

Marielle Lagers, Executive Director of the Netherlands Foreign Investment Agency in Taiwan, together with Renee Yeh, Senior Associate at Briddge, highlighted the role of Dutch incentives and taxation frameworks in supporting companies considering European investment.

For biotechnology businesses, however, investment decisions are rarely driven by incentives alone. The real calculation involves the entire operating environment—from talent and research partnerships to regulatory access, financing options and the ability to scale internationally.

This is where the Dutch proposition becomes particularly relevant. By combining a mature life sciences ecosystem with connectivity to the wider European market, the Netherlands is positioning itself not simply as a location for establishing an office, but as a potential platform from which companies can build their European growth strategies.

Regulation Is Becoming a Strategic Capability

The centrepiece of the session was a detailed discussion on European regulation led by Sebastian Asprella, Programme Lead, EU Competitiveness, Regulatory Science and Innovation at the European Medicines Agency, and Thomas Ballotti, Scientific Officer at EMA.

Their session, “Demystifying EU Regulations,” focused on the regulatory support tools available to developers of innovative medicines and technologies.

For emerging biotech companies, particularly those entering Europe for the first time, regulation can often appear to be a barrier encountered towards the end of product development. The more important message emerging from the discussion was that regulatory strategy should instead be treated as an integral part of innovation itself.

Early scientific and regulatory engagement can help developers understand evidence expectations, identify potential gaps in development programmes and make better-informed decisions before significant capital and time have been committed.

This is especially important as biotechnology enters increasingly complex scientific territory. Advanced therapies, precision medicines and emerging technology platforms do not always fit neatly within traditional development models. The ability of innovators and regulators to engage early therefore becomes increasingly important to translating breakthrough science into products that can ultimately reach patients.

Europe’s Opportunity Is Also Asia’s Opportunity

The significance of the session extended beyond the Netherlands.

Across Asia, biotechnology ecosystems are producing increasingly sophisticated technologies and globally ambitious companies. Taiwan, in particular, is strengthening its capabilities across drug development, precision medicine, advanced therapies and biomanufacturing.

As these companies look internationally, Europe represents both a major market and an important development ecosystem. Yet successful entry will depend on understanding that regulation, investment and market access cannot be addressed independently.

The Netherlands is making a compelling case for being the place where these conversations can converge.

With EMA headquartered in Amsterdam and a wider ecosystem designed to attract international life sciences investment, the country occupies a distinctive position in Europe’s biotechnology landscape. For Asian companies, that proximity—both institutional and commercial—could become increasingly valuable as they build global development strategies.

From Regulatory Compliance to Competitive Advantage

Perhaps the most important takeaway from the session was a shift in perspective.

Regulation is often discussed as something innovation must overcome. But for companies operating in highly complex and capital-intensive industries, regulatory understanding can itself become a competitive advantage.

Companies that engage earlier, design development programmes with regulatory expectations in mind and establish themselves within ecosystems capable of supporting international expansion may be better positioned to move from promising science to globally viable products.

The session at BIO Asia–Taiwan 2026 therefore captured a broader change taking place across the global biotechnology industry.

The next generation of successful biotech companies will not compete on science alone. They will compete on how effectively they connect science with regulation, capital and market access.

And at precisely that intersection, the Netherlands is positioning itself as an increasingly important gateway between Asia’s biotechnology ambitions and Europe’s healthcare market.